CN116173085B - 一种刺五加提取物及其制备方法和应用 - Google Patents
一种刺五加提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116173085B CN116173085B CN202310173066.XA CN202310173066A CN116173085B CN 116173085 B CN116173085 B CN 116173085B CN 202310173066 A CN202310173066 A CN 202310173066A CN 116173085 B CN116173085 B CN 116173085B
- Authority
- CN
- China
- Prior art keywords
- acanthopanax
- acid
- extract
- preparation
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000000605 extraction Methods 0.000 title description 16
- 241001632410 Eleutherococcus senticosus Species 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 35
- 102000004190 Enzymes Human genes 0.000 claims abstract description 32
- 108090000790 Enzymes Proteins 0.000 claims abstract description 32
- 229940088598 enzyme Drugs 0.000 claims abstract description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 17
- 108010059892 Cellulase Proteins 0.000 claims abstract description 16
- 229940106157 cellulase Drugs 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 108091005804 Peptidases Proteins 0.000 claims abstract description 15
- 239000004365 Protease Substances 0.000 claims abstract description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 15
- -1 pectase Proteins 0.000 claims abstract description 14
- 101710130006 Beta-glucanase Proteins 0.000 claims abstract description 13
- 230000007062 hydrolysis Effects 0.000 claims abstract description 13
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 13
- 238000009736 wetting Methods 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 12
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 208000022531 anorexia Diseases 0.000 claims description 10
- 206010061428 decreased appetite Diseases 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 claims description 7
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 6
- GYFFKZTYYAFCTR-JUHZACGLSA-N 4-O-trans-caffeoylquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-JUHZACGLSA-N 0.000 claims description 6
- GYFFKZTYYAFCTR-UHFFFAOYSA-N 5-O-(6'-O-galloyl)-beta-D-glucopyranosylgentisic acid Natural products OC1CC(O)(C(O)=O)CC(O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 6
- 229940074393 chlorogenic acid Drugs 0.000 claims description 6
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 6
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 6
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- GYFFKZTYYAFCTR-LMRQPLJMSA-N cryptochlorogenic acid Natural products O[C@H]1C[C@@](O)(C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-LMRQPLJMSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- LUKOBZAEANPCPQ-PKOSOWSZSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8-hydroxy-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trih Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LUKOBZAEANPCPQ-PKOSOWSZSA-N 0.000 claims description 5
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 claims description 5
- YDDUMTOHNYZQPO-BBLPPJRLSA-N 1,3-di-O-caffeoylquinic acid Natural products O[C@@H]1C[C@@](C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc1ccc(O)c(O)c1)C(O)=O YDDUMTOHNYZQPO-BBLPPJRLSA-N 0.000 claims description 5
- DSHJQVWTBAAJDN-SMKXDYDZSA-N 4-caffeoylquinic acid Natural products CO[C@@]1(C[C@@H](O)[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@H](O)C1)C(=O)O DSHJQVWTBAAJDN-SMKXDYDZSA-N 0.000 claims description 5
- LTSOENFXCPOCHG-GQCTYLIASA-N 4-chloro-6-[[(e)-3-oxobut-1-enyl]amino]-1-n-prop-2-enylbenzene-1,3-disulfonamide Chemical compound CC(=O)\C=C\NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(=O)(=O)NCC=C LTSOENFXCPOCHG-GQCTYLIASA-N 0.000 claims description 5
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 claims description 5
- LUKOBZAEANPCPQ-UHFFFAOYSA-N Acanthopanaxoside E Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1O LUKOBZAEANPCPQ-UHFFFAOYSA-N 0.000 claims description 5
- GYFFKZTYYAFCTR-ZNEHSRBWSA-N Cryptochlorogensaeure Natural products O[C@@H]1C[C@@](O)(C[C@@H](O)[C@@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-ZNEHSRBWSA-N 0.000 claims description 5
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 5
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 3
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 19
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 239000012528 membrane Substances 0.000 description 51
- 241000196324 Embryophyta Species 0.000 description 25
- 239000000919 ceramic Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000005374 membrane filtration Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000012459 cleaning agent Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000012465 retentate Substances 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920002488 Hemicellulose Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FFDULTAFAQRACT-JSGUJALWSA-N Eleutheroside E Chemical compound COC1=CC([C@@H]2[C@@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-JSGUJALWSA-N 0.000 description 3
- FFDULTAFAQRACT-MWBGVTEFSA-N Eleutheroside E Natural products COc1cc(cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H]3OC[C@H]4[C@H]3CO[C@@H]4c5cc(OC)c(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c(OC)c5 FFDULTAFAQRACT-MWBGVTEFSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000001724 microfibril Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NYFPVHPLEGGWHZ-DIUPZIBKSA-N [(2s,3r,4s,5s,6r)-6-[[(2r,3r,4r,5s,6r)-6-(acetyloxymethyl)-3,4-dihydroxy-5-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2s,3 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@@H](CC(C)(C)CC3)C=3[C@@]([C@]5(C)CC[C@H]6C(C)(C)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)CC[C@]6(C)[C@H]5CC=3)(C)CC4)O2)O)[C@H](O)[C@H]1O NYFPVHPLEGGWHZ-DIUPZIBKSA-N 0.000 description 2
- NYFPVHPLEGGWHZ-UHFFFAOYSA-N acanthopanaxoside B Natural products OC1C(O)C(O)C(C)OC1OC1C(COC(C)=O)OC(OCC2C(C(O)C(O)C(OC(=O)C34C(CC(C)(C)CC3)C=3C(C5(C)CCC6C(C)(C)C(OC7C(C(O)C(O)CO7)OC7C(C(O)C(O)C(CO)O7)O)CCC6(C)C5CC=3)(C)CC4)O2)O)C(O)C1O NYFPVHPLEGGWHZ-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- MQSVACYEBUOKAY-AEAHGDTJSA-N Periplocoside N Natural products O([C@@H](C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1)[C@H]1O[C@@H](C)[C@@H](O)[C@@H](O)C1 MQSVACYEBUOKAY-AEAHGDTJSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010058120 Tuberculosis liver Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种刺五加提取物及其制备方法和应用,本发明的刺五加提取物通过将刺五加植物破碎、水润、水解得到,其中水解过程加入由纤维素酶、果胶酶、β‑葡聚糖酶、植物蛋白酶组成的专用复合酶试剂,显著提高了刺五加提取物的有效成分含量,本发明制备的刺五加提取物可用于制备调节内分泌系统、改善厌食症药物。
Description
技术领域
本发明属于医药技术领域,具体涉及一种刺五加提取物及其制备方法和应用。
背景技术
刺五加(Radix Acanthopanacis Senticosl)为五加科五加属植物的根、根茎及茎,主要分布在中国东北部、俄罗斯远东地区、日本北海道及朝鲜等地。始见于东汉《神农本草经》,别名为五加参、老虎钌自、刺拐棒(东北)。《本草纲目》记载刺五加能“补力益精,明目下气”,能“补五劳七伤,久服轻身耐老”,具有益气健脾,补肾安神之功效。
刺五加的主要功效成分为酚苷类及其某些苷元类成分,主要包括刺五加总苷和总黄酮等;刺五加总苷具有7种型式,其主要活性成分为刺五加苷B、刺五加苷E;刺五加苷B又称紫丁香苷(Syringin),相对含量最多,也是刺五加中的主要药效成分之一,具有抗疲劳、增强免疫力、护肝和释放乙酰胆碱,增加胰岛素分泌,防辐射等作用;刺五加苷E具有缓解压力、抗焦虑、抗应激、抗溃疡和抗疲劳等作用;
刺五加总黄酮是刺五加中重要的天然有效活性成分,具有广泛的药理活性,能扩张血管,增加冠状动脉血流量,降低心肌耗氧量,抗心肌缺血,改善心电图,抗异位心律,降低血压,镇静安神。由于刺五加总黄酮的多种生物活性及良好的临床效果,多年来在国内外已成为中药提取及中草药现代化研究的焦点之一。
常用中药材约90%为植物类药材,植物细胞由细胞壁及原生质体组成,细胞壁是由纤维素、半纤维素、果胶质、木质素等物质构成的致密结构,一般分为3层,即胞间层、初生壁和次生壁。胞间层的主要成分为果胶质,初生壁则主要由纤维素、半纤维素和果胶质组成。初生壁的结构十分复杂,由纤维素分子组成的微纤丝构成了其基本骨架,在微纤丝之间的空隙中,填着果胶质和半纤维素的胶体状物质。和初生壁一样,次生壁的骨架也是由纤维素分子组成的微纤丝构成。在中药提取过程中,细胞原生质体中的有效成分向提取介质扩散时,必须克服细胞壁及细胞间质的双重阻力,所以通过选用一些恰当的酶类,如纤维素酶、半纤维素酶、果胶酶等作用于药用植物细胞,使细胞壁及细胞间质中的纤维素、半纤维素、果胶等物质降解,破坏细胞壁的致密结构,引起细胞壁及细胞间质结构产生局部疏松、膨胀、崩溃等变化,减小细胞壁、细胞间质等传质屏障对有效成分从胞内向提取介质扩散的传质阻力,真正从传质角度促进有效成分提取率提高。
目前,刺五加主要功能活性成分的提取包括水提、醇提和超临界CO2萃取等方法,其中超临界CO2萃取的选择性高、操作时间短、有效成分得率高,但其受处理量的限制,产量低,目前工业开发难度较大,因而目前仍以水提、有机溶剂提取为主,且多数仅以单一成分作为衡量提取工艺参数优劣的指标,难以保证刺五加的全部有效成分得到充分的提取分离和利用。也有少部分采用酶法进行提取刺五加有效成分,包括纤维素酶、果胶酶、蛋白酶等不同种类的酶,例如专利CN105131142A公开了一种刺五加多糖的工业化生产方法及其应用,该专利采用超临界萃取、酶解(蛋白酶:纤维素酶:果胶酶=2~4:1~2:0~0.5)、树脂吸附,获得刺五加苷E提取率达到90%以上,多糖含量得率95%以上,该方法制备的刺五加多糖在结核病肝损伤方面效果较好,但提取的整体有效成分转移率低,且制备方法复杂,工业化应用上成本高;CN112089741A公开了一种刺五加提取物组合物、提取方法及其注射液,采用水提醇沉后,用大孔吸附树脂吸附,再用乙醇洗脱得到,提取物组分包括刺五加苷B、刺五加苷E、果糖、葡萄糖、蔗糖、麦芽糖、绿原酸、隐绿原酸、新绿原酸,但该专利方法获得的刺五加提取物有效成分含量少,提取率低。
综上所述,制备一种专用刺五加提取物的酶制剂在中药提取中具有广泛的应用前景,甚至可通过酶反应改变中草药目标活性物质的结构,有望制备出高附加值的医药产品,对推动医药行业的发展具有重要意义。
发明内容
针对现有技术中存在的问题,本发明提供了一种刺五加提取物及其制备方法和应用。
第一方面,本发明提供了一种刺五加提取物的制备方法,包括以下步骤:
S1、因北方采收刺五加为冬季,将刺五加植物的根、根茎和/或茎洗净,冬季气温零下10度以下,在室外冷冻干燥后,使用粉碎机,充分破碎到60~80目,然后进行水润,水润时间为3~12小时;
S2、取步骤S1水润后的刺五加置于5~8倍质量的水中,然后加入专用复合酶试剂,搅拌均匀,进行水解;
S3、将步骤S2水解后的料液进行灭酶,过滤浓缩后得到刺五加提取物。
进一步地,所述步骤S2中水浴的pH为4.1~5.0,优选为4.8。
进一步地,所述步骤S2中的pH采用草酸、乙酸或柠檬酸进行调节。
进一步地,所述步骤S2中的水解温度为15~62℃,优选为50±5℃。
进一步地,所述步骤S2中的水解时间为6~24h。
进一步地,所述步骤S2中的专用复合酶试剂为纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶组成。
更进一步地,所述专用复合酶试剂中纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶组成的质量比为1:(0.5~2.0):(0.1~1.0):(1.0~1.8)。
进一步地,所述步骤S2中专用复合酶添加量为底物重量的1%~6%,优选为3%~6%。
进一步地,所述步骤S3中水解过程进行搅拌,每5分钟充分搅动一次,水解时间缩短一半。
进一步地,所述步骤S3中陶瓷膜过滤浓缩采用陶瓷膜分离实验装置(151101的陶瓷膜样品,BCM-200/500-19*31*1016,膜过滤孔径50nm、100nm、200nm)和一套2540有机膜浓缩实验装置(反渗透膜2540),装置的膜面积为0.24×1=0.24m2,该装置由进料泵、循环泵、膜组件等组成,进料泵提供系统压力,循环泵提供系统流量,可采用蒸汽或冷却水作为加热或冷却介质,保证维持系统的工艺温度(5-80℃),采用批处理间歇式操作过程,连续地对料液进行过滤,当料液截留物浓缩到一定浓缩倍数时,把陶瓷膜滤液转移到有机膜设备进行浓缩,提高有效成分的收率,每批料液过滤完成后,使用碱和酸等清洗剂进行膜的再生,以便下次再用。
第二方面,本发明提供了由上述刺五加提取物的制备方法制得的刺五加提取物。
进一步地,按重量份数计,所述刺五加提取物中含有紫丁香苷0.5~2.5份、刺五加苷E0.5~2.5份、异嗪皮啶0.1~2.0份、原儿茶酸0.05~0.5份、香草酸0.25~1.05份、绿原酸0.5~1.5份、4-咖啡酰奎宁酸0.3~1.5份、5-咖啡酰奎宁酸0.5~1.5份、1,5-二咖啡酰奎宁酸0.1~1.0份、葡萄糖0.1~1.5份、麦芽糖0.1~0.5份、木糖0.15~1.0份、半乳糖0.2~1.5份。
第三方面,本发明还提供了刺五加提取物在制备调节神经系统药物、免疫系统药物、内分泌系统药物、心脑血管系统药物和/或生殖系统、改善厌食症药物中的应用;
进一步地,所述药物中还包括刺五加提取物药学上可接受的载体或稀释剂组成;
进一步地,所述内分泌系统药物包括但不局限于调节更年期综合症、糖尿病药物、改善睡眠、调节血糖等。
进一步地,所述药物剂型包括但不局限于注射液、冻干粉针剂、片剂、颗粒剂、胶囊剂、糖浆剂或合剂。
与现有技术相比,本发明的有益效果如下:
本发明通过采用由纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶组成的专用复合酶试剂对刺五加植物进行水解,显著提高了刺五加提取物中有效成分含量,相比现有技术中仅采用纤维素酶和果胶酶、或纤维素酶和果胶酶和植物蛋白酶的复合酶进行水解,本发明的专用复合酶制剂对刺五加提取物的有效成分含量提高有显著进步;同时,本发明制备的刺五加提取物组合物对调节睡眠、调节血糖水平、改善厌食症效果显著。
附图说明
图1为刺五加提取物对厌食症大鼠摄食量的影响;
图2为刺五加提取物对厌食症大鼠体质量的影响。
具体实施方式
本发明下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂,均为市售产品。
除非另有定义,本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不用于限制本发明。
本发明的术语“包括”和“具有”以及它们任何变形,意图在于覆盖不排他的包含。例如包含了一系列步骤的过程、方法、装置、产品或设备没有限定于已列出的步骤或模块,而是可选地还包括没有列出的步骤,或可选地还包括对于这些过程、方法、产品或设备固有的其它步骤。
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
以下实施例对本发明做进一步的描述,但该实施例并非用于限制本发明的保护范围。
实施例1本发明刺五加提取物及其制备方法
S1、将刺五加植物的根、根茎和/或茎洗净,室外10度以下,冷冻干燥后充分破碎至80目,然后进行水润,水润时间为12h;
S2、取步骤S1水润后的刺五加置于6倍质量的水中,温度为50℃,乙酸调节pH为4.8,然后加入专用复合酶试剂(纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:0.5:0.5:1.2),专用复合酶试剂添加量为底物重量的5%,搅拌均匀,水解过程进行搅拌,每5分钟充分搅动一次,水解15h;
S3、将步骤S2水解后的料液进行灭酶,使用陶瓷膜过滤浓缩,得到刺五加提取物。
所述陶瓷膜过滤浓缩采用陶瓷膜分离实验装置(151101的陶瓷膜样品,BCM-200/500-19*31*1016,膜过滤孔径100nm)和一套2540有机膜浓缩实验装置(反渗透膜2540),装置的膜面积为0.24×1=0.24m2,该装置由进料泵、循环泵、膜组件等组成,进料泵提供系统压力,循环泵提供系统流量,采用蒸汽加热介质,保证维持系统的工艺温度(55℃),采用批处理间歇式操作过程,连续地对料液进行过滤,当料液截留物浓缩到2倍浓缩倍数时,把陶瓷膜滤液转移到有机膜设备进行浓缩,提高有效成分的收率,每批料液过滤完成后,使用碱和酸等清洗剂进行膜的再生,以便下次再用。
实施例2本发明刺五加提取物及其制备方法
S1、将刺五加植物的根、根茎和/或茎洗净,室外10度以下,干燥后充分破碎80目,然后进行水润,水润时间为12h;
S2、取步骤S1水润后的刺五加置于6倍质量的水中,温度为45℃,乙酸调节pH为4.5,然后加入专用复合酶试剂(纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:0.8:0.1:1.0),专用复合酶试剂添加量为底物重量的3%,搅拌均匀,水解过程进行搅拌,每5分钟充分搅动一次,水解24h;
S3、将步骤S2水解后的料液进行灭酶,使用陶瓷膜过滤浓缩,得到刺五加提取物。
所述陶瓷膜过滤浓缩采用陶瓷膜分离实验装置(151101的陶瓷膜样品,BCM-200/500-19*31*1016,膜过滤孔径100nm)和一套2540有机膜浓缩实验装置(反渗透膜2540),装置的膜面积为0.24×1=0.24m2,该装置由进料泵、循环泵、膜组件等组成,进料泵提供系统压力,循环泵提供系统流量,采用蒸汽加热介质,保证维持系统的工艺温度(55℃),采用批处理间歇式操作过程,连续地对料液进行过滤,当料液截留物浓缩到2倍浓缩倍数时,把陶瓷膜滤液转移到有机膜设备进行浓缩,提高有效成分的收率,每批料液过滤完成后,使用碱和酸等清洗剂进行膜的再生,以便下次再用。
实施例3本发明刺五加提取物及其制备方法
S1、将刺五加植物的根、根茎和/或茎洗净,室外10度以下,干燥后充分破碎60目,然后进行水润,水润时间为12h;
S2、取步骤S1水润后的刺五加置于6倍质量的水中,温度为55℃,乙酸调节pH为4.1,然后加入专用复合酶试剂(纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:2.0:1.0:1.0),专用复合酶试剂添加量为底物重量的6%,搅拌均匀,水解过程进行搅拌,每5分钟充分搅动一次,水解10h;
S3、将步骤S2水解后的料液进行灭酶,使用陶瓷膜过滤浓缩,得到刺五加提取物。
所述陶瓷膜过滤浓缩采用陶瓷膜分离实验装置(151101的陶瓷膜样品,BCM-200/500-19*31*1016,膜过滤孔径100nm)和一套2540有机膜浓缩实验装置(反渗透膜2540),装置的膜面积为0.24×1=0.24m2,该装置由进料泵、循环泵、膜组件等组成,进料泵提供系统压力,循环泵提供系统流量,采用蒸汽加热介质,保证维持系统的工艺温度(55℃),采用批处理间歇式操作过程,连续地对料液进行过滤,当料液截留物浓缩到2倍浓缩倍数时,把陶瓷膜滤液转移到有机膜设备进行浓缩,提高有效成分的收率,每批料液过滤完成后,使用碱和酸等清洗剂进行膜的再生,以便下次再用。
实施例4本发明刺五加提取物及其制备方法
S1、将刺五加植物的根、根茎和/或茎洗净,室外10度以下,干燥后充分破碎60目,然后进行水润,水润时间为12h;
S2、取步骤S1水润后的刺五加置于6倍质量的水中,温度为62℃,乙酸调节pH为4.8,然后加入专用复合酶试剂(纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:0.8:1.0:1.8),专用复合酶试剂添加量为底物重量的1%,搅拌均匀,水解过程进行搅拌,每5分钟充分搅动一次,水解6h;
S3、将步骤S2水解后的料液进行灭酶,使用陶瓷膜过滤浓缩,得到刺五加提取物。
所述陶瓷膜过滤浓缩采用陶瓷膜分离实验装置(151101的陶瓷膜样品,BCM-200/500-19*31*1016,膜过滤孔径100nm)和一套2540有机膜浓缩实验装置(反渗透膜2540),装置的膜面积为0.24×1=0.24m2,该装置由进料泵、循环泵、膜组件等组成,进料泵提供系统压力,循环泵提供系统流量,采用蒸汽加热介质,保证维持系统的工艺温度(55℃),采用批处理间歇式操作过程,连续地对料液进行过滤,当料液截留物浓缩到2倍浓缩倍数时,把陶瓷膜滤液转移到有机膜设备进行浓缩,提高有效成分的收率,每批料液过滤完成后,使用碱和酸等清洗剂进行膜的再生,以便下次再用。
试验例一、实施例1~4制备的刺五加提取物中有效成分含量的测定
采用高效液相色谱法(中国药典2020年版四部通则0512)测定实施例1~4刺五加组提取物组合物中的有效成分的含量),色谱条件与系统适用性试验应用ACQUITY UPLCHSS T3(2.1×100mm,1.8μm)色谱柱;以0.5%甲酸-水溶液(V/V)为流动相A,以乙腈溶液(V/V)为流动相B,按表1中的洗脱程序进行洗脱,其中柱温为35℃,流速为0.5ml/min,检测波长:紫丁香苷、刺五加苷E、原儿茶酸、香草酸、葡萄糖、麦芽糖、木糖、半乳糖为275nm,异嗪皮啶为344nm,绿原酸、4-咖啡酰奎宁酸、5-咖啡酰奎宁酸、1,5-二咖啡酰奎宁酸为321nm。
表1流动相洗脱程序
高效液相色谱法测定实施例1~4制备的刺五加提取物有效成分含量的具体方法如下:
(1)对照品溶液的制备
取紫丁香苷、刺五加苷E、异嗪皮啶、原儿茶酸、香草酸、绿原酸、4-咖啡酰奎宁酸、5-咖啡酰奎宁酸、1,5-二咖啡酰奎宁酸、葡萄糖、麦芽糖、木糖、半乳糖对照品适量,精密称定,分别加15%甲醇溶液超声溶解定容,制成的混合溶液,用0.22μm的微孔滤膜滤过,取续滤液即得。
(2)供试品溶液的制备
精密量取实施例1~4中刺五加提取物5ml,置10ml量瓶中,加15%甲醇溶液稀释至刻度,摇匀,用0.22μm的微孔滤膜滤过,取续滤液即得。
(3)测定法分别精密吸取对照品溶液与供试品溶液各2μl,注入液相色谱仪中测定。
按照上述高效液相色谱法测定的实施例1~4制备的刺五加提取,得到的刺五加提取物有效成分含量如表2所示;
表2
对比例1
与实施例1的区别在于,专用复合酶中纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:0.5:0:1.2,其余步骤与实施例1一致。
对比例2
与实施例1的区别在于,专用复合酶中纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:0.5:1.2:1.2,其余步骤与实施例1一致。
对比例3
与实施例1的区别在于,专用复合酶中纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的质量比为1:2.2:0.5:0.5,其余步骤与实施例1一致。
对比例4
与实施例1的区别在于,水解pH为4.0,其余步骤与实施例1一致。
对比例5
与实施例1的区别在于,专用复合酶的添加量为6.5%,其余步骤与实施例1一致。
试验例二、对比例1~5制备的刺五加提取物中有效成分含量
按照试验例一种高效液相色谱法,对比例1~5制备的刺五加提取物的有效成分含量测定结果如表3所示;
表2
由试验例一结果和试验例二结果对比可知,本发明的刺五加提取物的制备方法对紫丁香苷、刺五加苷E、异嗪皮啶、原儿茶酸、香草酸、绿原酸、4-咖啡酰奎宁酸、5-咖啡酰奎宁酸、1,5-二咖啡酰奎宁酸、葡萄糖、麦芽糖、木糖、半乳糖成分含量的提高有显著效果,其中专用复合酶中纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶的成分和比例对刺五加提取物有效成分的影响更显著。
试验例三、刺五加提取物对血糖的影响
实验动物:昆明种小鼠,体重18-22g,雌雄各半。
实验试剂:四氧嘧啶,购自Sigma公司。
实验分组:空白对照组、模型组、实施例1-4组、对比例1-5组。
实验方法如下:
模型制备:将四氧嘧啶用生理盐水配成2%水溶液(现用现配)。
取昆明种小鼠,雌雄各半,按四氧嘧啶溶液50mg/kg的剂量,对禁食12小时后的小
鼠进行尾静脉注射。连续饲养3天后,禁食12小时,眼眶采血,分离血清,测定空腹血糖,以血糖大于14mmol/l作为糖尿病模型小鼠。
分组给药:取糖尿病模型小鼠80只,雌雄各半,随机分为8组,每组10只,分别为实施例1-4组、对比例1-5组和模型组;另取重量相近正常昆明种小鼠10,雌雄各半,作为空白对照组。
实施例1-4组、对比例1-5组分别灌胃给予实施例1-4的刺五加提取物、对比例1-5的刺五加提取物,剂量均为1.0g生药量/kg,模型组和空白对照组分别按照15ml/kg体重灌胃给予同体积的生理盐水,连续灌胃15天,每天观察小鼠外貌特征的改变。
试验结束后对试验动物禁食12小时,眼眶静脉丛采血,测定空腹血糖。
统计学处理:本实验数据统计分析使用SPSS统计软件完成。
实验结果:
对四氧嘧啶所致小鼠血糖升高的影响,见表3:
表3
注:模型组相比,#P<0.05,##P<0.01,与空白组相比,*P<0.05。
由表3结果显示,本发明制备方法制备的刺五加提取物具有显著的降血糖作用。
试验例四、刺五加提取物对调节睡眠的影响
(1)试验方法:
取昆明种小鼠,体重18~22g,雌雄各半,温度控制在24±2℃,湿度55±15%,12:12h明暗交替,所用实验动物均自由饮食、水,实验前一天应禁食、水,取60只小鼠放置实验室中一周,使之适应环境,随机分为5组,每组12只,分别为空白组(0.2mL/20g),阳性对照组(0.2mL/20g)、制备的刺五加提取物高、中、低剂量组(0.2mL/20g),经灌胃途径给药,空白组/阳性对照组均给予同体积蒸馏水,同时给予地西泮片(2.5mg/kg),实施例制备的刺五加提取物高、中、低剂量组分别给予4、2、1mL/kg,对比例制备的刺五加提取物给予4mL/kg,每日灌胃一次,连续灌胃30天,末次给药30min后各组均腹腔注射戊巴比妥钠(55mg/kg,注射容积为0.2ml/20g),并记录睡眠觉醒时间。
(2)统计分析:
本实验数据统计分析使用SPSS统计软件完成;
(3)实验结果
刺五加提取物延长阈剂量戊巴比妥钠所致小鼠睡眠的影响,结果见表4;
表4
注:阳性对照组相比,#P<0.05,##P<0.01,与空白组相比,**P<0.01。
由表4结果显示,在连续给药30d后,本发明制备方法制备的刺五加提取物对小鼠的睡眠调节的作用明显。
试验例五、刺五加提取物对治疗厌食症的影响
(1)试验方法
将50只SPF级SD大鼠,雌雄各半,适应性喂养3天后随机分成6组,空白组10只和实验组50只,空白组给予常规饲料喂养,实验组给予厌食症模型饲料(奶粉、鱼松、豆粉、玉米粉、白糖、鲜鸡蛋、鲜肥肉(1:1:2:1:1:1.8:2),将以上原材料混匀后捏成小饼干状,约2cm×3cm,烤盘盛放,160℃烤制30min,恢复室温后密封包装,4℃冰箱保存),造模10天后模型组摄食量及体质量分别低于空白组53%和12%,造模成功,将造模成功的实验组再次分成模型对照组、阳性对照组和高、中、低剂量组(实施例1),每组10只,每组给予常规饲料喂养,空白组和模型对照组给予饮用水10g/kg,实施例高、中、低剂量组分别给予刺五加提取物5mL/kg、2.5ml/kg、1.25ml/kg,对比例给予刺五加提取物5mL/kg,每日灌胃1次,共7天,每日上午10点记录大鼠摄食量、体质量;
(2)实验结果
刺五加提取物治疗厌食症的结果见附图1~2;
本试验例中,与空白组相比,模型组具有显著性差异,p<0.05,与模型组相比,阳性对照组、高中低剂量组、对比例4和对比例5具有显著性差异,p<0.05,而对比例1~3不具有显著性差异p>0.05;由附图1结果可知,本发明制备的刺五加提取物明显增加厌食症大鼠的摄食量,高、中剂量组可基本达到阳性对照组的恢复能力,7~14天摄食量可恢复至正常水平,附图2结果表明,本发明制备的刺五加提取物可提高厌食症大鼠的体质量,高、中剂量组与阳性对照组恢复能力相当。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (6)
1.一种刺五加提取物的制备方法,其特征在于,包括以下步骤:
S1、将刺五加植物的根、根茎和/或茎洗净,干燥后充分破碎,然后进行水润,水润时间为3~12小时;
S2、取步骤S1水润后的刺五加置于5~8倍质量的水中,然后加入专用复合酶试剂,专用复合酶添加量为底物质量的1%~6%,所述专用复合酶试剂由质量比为1 : (0.5~2.0) :(0.1~1.0) : (1.0~1.8)的纤维素酶、果胶酶、β-葡聚糖酶、植物蛋白酶组成,搅拌均匀,进行水解,所述水解pH为4.1~4.8;
S3、将步骤S2水解后的料液进行灭酶,过滤浓缩后得到刺五加提取物。
2.根据权利要求1所述的刺五加提取物的制备方法,其特征在于,所述步骤S2中水解pH采用草酸、乙酸或柠檬酸进行调节。
3.根据权利要求1所述的刺五加提取物的制备方法,其特征在于,所述步骤S2中的水解温度为15~62℃。
4.一种根据权利要求1~3任一项所述的制备方法制得的刺五加提取物。
5.根据权利要求4所述的刺五加提取物,其特征在于,所述刺五加提取物中含有紫丁香苷、刺五加苷E、异嗪皮啶、原儿茶酸、绿原酸、香草酸、4-咖啡酰奎宁酸、5-咖啡酰奎宁酸和1,5-二咖啡酰奎宁酸、葡萄糖、麦芽糖、木糖、半乳糖。
6.根据权利要求4所述的刺五加提取物在制备调节内分泌系统、改善厌食症药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310173066.XA CN116173085B (zh) | 2023-02-27 | 2023-02-27 | 一种刺五加提取物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310173066.XA CN116173085B (zh) | 2023-02-27 | 2023-02-27 | 一种刺五加提取物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116173085A CN116173085A (zh) | 2023-05-30 |
CN116173085B true CN116173085B (zh) | 2024-04-30 |
Family
ID=86438046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310173066.XA Active CN116173085B (zh) | 2023-02-27 | 2023-02-27 | 一种刺五加提取物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116173085B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107595893A (zh) * | 2017-08-25 | 2018-01-19 | 广西中医药大学 | 一种经酶处理的中药饮片及其制备方法 |
-
2023
- 2023-02-27 CN CN202310173066.XA patent/CN116173085B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107595893A (zh) * | 2017-08-25 | 2018-01-19 | 广西中医药大学 | 一种经酶处理的中药饮片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
刺五加临床应用拓展研究;缪茂军等;江西省中医药学会2011年学术年会论文集;第1页第1-2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN116173085A (zh) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114177218B (zh) | 一种富含1-脱氧野尻霉素的桑叶提取物及其制备方法 | |
CN107412721A (zh) | 一种降血糖苦瓜多肽复方胶囊及其制备方法 | |
KR101341755B1 (ko) | 펙티나아제를 이용한 인삼 또는 홍삼의 파낙사디올 사포닌 대사체 강화 분획물 제조방법 | |
CN101401829A (zh) | 一种野金柴活性提取物及其制备方法和应用 | |
CN112159451A (zh) | 一种绞股蓝皂苷提取物及其制备方法 | |
CN107522761A (zh) | 一种分离纯化飞燕草素‑3‑o桑布双糖苷的方法及其降糖用途 | |
CN116173085B (zh) | 一种刺五加提取物及其制备方法和应用 | |
CN108771690B (zh) | 一种具有降血糖或降血脂作用的红冬蛇菰提取物及其制备方法和应用 | |
CN101463314A (zh) | 一种不易醉的酒及其解酒营养液的制作方法 | |
CN104491048B (zh) | 一种枇杷叶总倍半萜苷提取物及其制备方法与应用 | |
CN116251134B (zh) | 一种罗汉果根降血糖组合物、应用及制备方法 | |
CN114507297B (zh) | 一种桦树茸多糖提取物的制备及应用 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN109771483B (zh) | 一种从水辣蓼中提取高活性α-葡萄糖苷酶抑制剂的方法 | |
CN113925948B (zh) | 生姜总提取物或其活性成分的用途、药物组合物和制法 | |
CN109876021B (zh) | 富含聚炔类化合物的荷叶离褶伞提取物的制备方法及其降糖用途 | |
CN1861104B (zh) | 可用于治疗糖尿病和高脂血症的旋复花提取物 | |
CN108440477B (zh) | 一种从油桐叶中制备槲皮素的方法 | |
CN103285113B (zh) | 一种预防和/或治疗糖尿病的药物组合物 | |
CN113875844A (zh) | 互花米草提取物在植物源功能茶产品的应用及功能茶产品 | |
CN116392526B (zh) | 一种具有α-葡萄糖苷酶抑制活性的黄山楂提取物制备方法与应用 | |
CN107693597B (zh) | 一种抗心肌缺血的中药组合物及其制备方法和应用 | |
CN105920152B (zh) | 一种化橘红有效部位及其在制备治疗糖尿病心肌病的药物中的应用 | |
CN1205971C (zh) | 脑乐静颗粒剂 | |
CN100560569C (zh) | 一种莲子心生物碱提取物、其制备方法及其在制备心脑血管疾病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |